A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
851actual
Sites
152
Countries
Belgium, Canada, France +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study terminated due to strategic business decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-06-15 | actual | When the study began enrolling |
| Primary completion | 2025-11-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-12 | actual | The whole study's end, after follow-up |
| First posted | 2020-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Drug: Lasmiditan — also filed as LY573144
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with Pain Freedom (High Dose)
measured 2 Hours Postdose
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed